EyePoint Pharmaceuticals to Cut 53% of Workforce After Phase 3 Trial Failure

Key Facts

EyePoint Pharmaceuticals announced a 53% workforce reduction following disappointing Phase 3 clinical trial results. Investing.com reported that the layoffs are a direct response to the failure of a key late-stage trial, which has significantly impacted the company's drug development pipeline.

The massive job cuts serve as a cost-saving measure necessitated by the clinical setback. This strategic reduction highlights the pressure on the financial outlook for EyePoint Pharmaceuticals as the company navigates a loss of investor confidence following the trial failure.